ProShares Ultra Nasdaq Biotechnology BIB
122.13 USD -2.23 (-1.79%)
At closeNov 10, 2026, 4:00 PM EST
122.12 -0.01 -0.01%
After hours · Nov 10, 4:00 PM ET
121.16 Day range 122.49
71.56 52-week range 126.40
- YTD
- +53.08%
- 1 year
- +70.93%
- Market cap
- 107.99M
- EPS (ttm)
- 3.53
- P/E ratio
- 34.59
- YTD return
- +53.08%
- 1-year return
- +70.93%
- Volume
- 5.13K
- Avg volume
- 9.95K
- Open
- 122.39
- Previous close
- 124.36
- Day's range
- 121.16 – 122.49
- 52-week range
- 71.56 – 126.40
5D +5.88 (+4.97%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 59.52
- 200-day average
- 59.79
About ProShares Ultra Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
News
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Scheduled to Split on Thursday, November 19th 
ProShares Announces ETF Share Splits 
Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine 
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index - Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
- Biotechs Are Ripping Following IPAB Ruling
New Study Suggests Drug Prices Have Doubled Since 2011: What's It Mean For The Market? 
ProShares Releases 2 New Leveraged Biotech ETFs 
Why Investors Should Closely Watch Celgene - UCB Sales Rise in Q1 - Analyst Blog
Your note
Sign in to keep a note on BIB — it syncs with the Stock Master app.